NCIt definition : A bispecific, Fc domain-containing, monoclonal antibody with potential antineoplastic
activity. Plamotamab contains two antigen-recognition sites: one for human CD3, a
T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that
is exclusively expressed on B-cells during most stages of B-cell development and is
often overexpressed in B-cell malignancies. Upon administration, plamotamab binds
to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage
may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing
tumor B-cells. Inclusion of an Fc domain on the antibody prolongs the half-life of
the bispecific antibody and enhances T-cell-mediated tumor cell killing because the
agent is able to bind to Fc receptors.;
UNII : 5ENX424FNF;
CAS number : 2138442-31-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2138442-31-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)